# Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-once-weekly-semaglutide-versus-once-daily-insulin/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Vanita R. Aroda,Stephen C. Bain,Bertrand Cariou,Milivoj Piletič,Ludger Rose,Mads Axelsen,Everton Rowe,J. Hans DeVries |
| Citations | 452 |
| DOI | 10.1016/s2213-8587(17)30085-2 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2602700371 |
| PMID | 28344112 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Stephen C. Bain](https://scholariq.org/researchers/stephen-c-bain/)

## Paper journal

- [The Lancet Diabetes & Endocrinology](https://scholariq.org/journals/the-lancet-diabetes-and-endocrinology/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.